Sonire Therapeutics Awarded $13 Million Through NEDO Deep-Tech Startups Support Program (DTSU) to Advance Global Commercialization of Pancreatic Cancer Treatment
Non-dilutive funding will support the commercialization, development, and expansion strategy for Sonire's Ultrasound-Guided HIFU Platform
PALO ALTO, Calif., June 17, 2026 /PRNewswire/ -- Sonire Therapeutics, a U.S.-based clinical-stage medical device company pioneering non-invasive ultrasound therapies for cancer treatment, today announced that Sonire Therapeutics
